Hematopathology Eligible or CAR-t Cell Treatment
Conditions
Brief summary
This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
Retrospective inclusion : * Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center * If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive Prospective inclusion : * Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center. * Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019 * Patient deemed eligible for a treatment with CAR-T after a medical exam performed in a qualified center according to the ministerial order of 8 August 2019 * If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive.
Exclusion criteria
Patient not registered with the social security in France
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival from eligibility | 15 years |
| Overall survival from administration | 15 years |
| complete response rate | 15 years |
| Progression free survival | 15 years |
| Duration of response | 15 years |
| Delays between patient eligibility and CAR-T treatment | 15 years |
Countries
France
Contacts
Institut Curie
CHU Pontchaillou